Trace Medical buys majority stake in LiViliti after FDA clears CPAP sanitiser
What's the deal? Trace MedicalDealroom has a profile for this one. Try Dealroom → has acquired a majority interest in LiViliti Health ProductsDealroom has a profile for this one. Try Dealroom →, a Sarasota-based maker of CPAP and respiratory accessories. The deal value was undisclosed.
Why now? The acquisition follows LiViliti winning 510(k) clearance from the US Food and Drug Administration for its Paptizer 360, a Class II respiratory accessory microbial reduction device for CPAP equipment. The clearance opens the US market to the product.
What's the endgame? Trace Medical, founded in 2004, rents advanced respiratory equipment and provides biomedical services to skilled nursing facilities, rehabilitation centres, hospice, and home medical equipment providers. The deal pairs its nationwide distribution with LiViliti's hygiene technology, building on an existing strategic investment between the two.
"Partnering with Trace Medical under a majority acquisition provides us with the scale, logistical expertise, and distribution power necessary to make this technology accessible across the continuum of care," said Brian Sharpe, chief executive officer and founder of LiViliti.
Greg Apostolou, chief executive officer of Trace Medical, said the companies are "raising the standard of care for CPAP users and healthcare systems nationwide."
The signal: The deal reflects how established medical-device distributors are absorbing younger specialists to add FDA-cleared products to their networks. For LiViliti, founded in 2019, it trades independence for the reach needed to scale a newly approved device.
Read more: business.thepilotnews.com
Image credit: Generated with Gemini
